Rare Disease Leadership Dialogue Announced for October Summit
The National Organization for Rare Disorders (NORD) announced a CEO leadership dialogue featuring major pharmaceutical companies to discuss the next decade of rare disease treatment and progress.
Washington D.C. – The National Organization for Rare Disorders (NORD) has announced a high-level discussion focused on leadership in rare diseases for the coming decade. The dialogue will feature the chief executive officers of BioMarin, Jazz Pharmaceuticals, and Otsuka, alongside NORD's CEO.
The discussion is set to be moderated by Becky Quick, co-anchor of CNBC's "Squawk Box." The event, titled the NORD Breakthrough Summit, aims to examine what it takes to translate scientific advancements into patient progress. It is scheduled to take place in Washington D.C. on October 6, 2026.
The participating CEOs represent prominent entities within the pharmaceutical industry, with a specific focus on developing treatments for rare conditions. The conversation is expected to shed light on the challenges and opportunities involved in the research, development, and patient access to novel therapies for individuals affected by rare diseases.
The summit convenes stakeholders and experts from the rare disease community. Its objective is to foster dialogue and strategic development for the sector's future. NORD is recognized for its advocacy efforts on behalf of patients with rare disorders.